首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Psychedelic medicine

缩写:PSYCHEDELIC MED

ISSN:2831-4425

e-ISSN:2831-4433

IF/分区:5.0/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引92
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Michelle St Pierre,Lucas Standing,Yarissa Herman et al. Michelle St Pierre et al.
Background: A core component in the provision and receipt of appropriate medical care is trust and communication between patients and physicians. The use of psychedelics for therapeutic purposes (PTPs) has experienced gro...
Mitch Earleywine,Samantha G Gomez Mitch Earleywine
Many authors assert that those who provide psychedelic-assisted therapy (PAT) likely benefit from having personal experiences with psychedelics (PEP) as part of their training. Meta-analytic results confirm advantages of experiential learni...
Shannon Dames,Crosbie Watler,Pamela Kryskow et al. Shannon Dames et al.
Introduction: This perspective on experiential training delves into the potential benefits and counterarguments related to integrating firsthand experience of psychedelic-assisted therapy (PaT) to enhance the competency o...
Crystal Lederhos Smith,Nathan Sackett,Brian Connor Stark et al. Crystal Lederhos Smith et al.
Background: There is increasing interest in the use of psychedelics for therapeutic and recreational use. Research has been hindered by federal prohibition, put in place in 1970. Despite the regulatory difficulty, researc...
Banan Ramarushton,Heidemarie Blumenthal,Anthony Ryals et al. Banan Ramarushton et al.
Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and is associated with various other forms of psychopathology (e.g., eating pathology, obsessive-compulsive disorder, posttraumatic stress ...
Dale Terasaki Dale Terasaki
Introduction: Alcohol use disorder (AUD) is widespread and problematic in the United States, and current pharmacotherapy options have relatively modest effects. Therefore, novel interventions such as ketamine therapy have...
Dana DiRenzo,Frederick S Barrett,Jamie Perin et al. Dana DiRenzo et al.
Background: Psilocybin is a psychedelic drug with potential therapeutic effects in patients with mood and substance use disorders. Little is known about its impact on the immune system. ...
Amanda E Downey,Ellen R Bradley,Anna S Lerche et al. Amanda E Downey et al.
Background: As the field of psychedelic therapy grows, it is vital to consider who can safely engage with psilocybin therapy. In most modern clinical trials of psilocybin therapy, individuals with a family history of bipo...